Package Leaflet: Information for the User
Leflunomide ratiopharm 20mg film-coated tabletsEFG
Leflunomide
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the pack:
Leflunomide ratiopharm contains the active substance leflunomide, which belongs to a group of medicines called antirheumatic medicines.
Leflunomide ratiopharm is used to treat adult patients with active rheumatoid arthritis or active psoriatic arthritis.
The symptoms of rheumatoid arthritis include joint inflammation, swelling, difficulty moving, and pain. Other symptoms that affect the whole body include loss of appetite, fever, lack of energy, and anemia (reduction in the number of red blood cells in the blood).
The symptoms of active psoriatic arthritis include joint inflammation, swelling, difficulty moving, pain, red-colored plaques, and scaly skin (skin lesions).
Do not takeLeflunomide ratiopharm
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to take Leflunomide ratiopharm
Males who wish to have children should contact their doctor, who may advise them to stop treatment with Leflunomide ratiopharm, take certain medications to quickly and sufficiently eliminate Leflunomide ratiopharm from their body. In this case, a blood test will be necessary to ensure that Leflunomide ratiopharm has been sufficiently eliminated from their body, and then they should wait at least another 3 months before trying to have children.
Occasionally, Leflunomide ratiopharm may cause some problems in the blood, liver, lungs, or nerves of the arms or legs. It may also cause some severe allergic reactions (including drug rash with eosinophilia and systemic symptoms [DRESS syndrome]) or increase the risk of serious infections. For more information on these side effects, see section 4 (Possible side effects).
DRESS syndrome initially appears with symptoms similar to those of the flu and a skin rash on the face, followed by a widespread skin rash with fever, elevated liver enzyme levels in the blood, and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.
Your doctor will perform blood testsat regular intervals, before and during treatment with Leflunomide ratiopharm, to monitor blood cells and liver function. Your doctor should also regularly check your blood pressure, as Leflunomide ratiopharm may cause an increase in blood pressure.
Consult your doctor if you experience chronic diarrhea of unknown origin. You may need to undergo additional tests to establish a differential diagnosis.
Tell your doctor if you develop a skin ulcer during treatment with Leflunomide ratiopharm (see section 4).
Children and adolescents
The use of Leflunomide ratiopharm is not recommended in children and adolescents under 18 years of age.
Other medicines and Leflunomide ratiopharm
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes medicines obtained without a prescription.
This is especially important if you are taking:
If you are taking a non-steroidal anti-inflammatory medicine(NSAIDs) and/or corticosteroids, you may continue to take them after starting treatment with Leflunomide ratiopharm.
Vaccinations
Consult your doctor if you need to be vaccinated. Some vaccines may not be given while you are being treated with Leflunomide ratiopharm or for a certain period after stopping treatment.
Taking Leflunomide ratiopharm with food, drinks, and alcohol
Leflunomide ratiopharm can be taken with or without food.
Do notdrink alcohol during treatment with Leflunomide ratiopharm. Drinking alcohol during treatment with Leflunomide ratiopharm may increase the risk of liver damage.
Pregnancy and breastfeeding
Do nottake Leflunomide ratiopharm if you are or think you may be pregnant. If you are pregnant or become pregnant while taking Leflunomide ratiopharm, there is an increased risk of having a child with serious birth defects. Women of childbearing age must not take Leflunomide ratiopharm without using reliable contraceptive methods.
Tell your doctor if you plan to become pregnant after stopping treatment with Leflunomide ratiopharm, as it is necessary to ensure that there are no remaining amounts of Leflunomide ratiopharm in your body before becoming pregnant. The elimination of the medicine from the body may take up to 2 years. This time period can be reduced to a few weeks by taking certain medicines that accelerate the elimination of Leflunomide ratiopharm from the body.
In any case, before becoming pregnant, a blood test will be necessary to confirm that Leflunomide ratiopharm has been sufficiently eliminated from your body, and after this test, you should wait at least 1 month before becoming pregnant.
For more information on laboratory tests, contact your doctor.
If you suspect that you may be pregnant during treatment with Leflunomide ratiopharm or in the 2 years after treatment, you must contact your doctor immediatelyfor a pregnancy test. If the test confirms that you are pregnant, your doctor may suggest that you start treatment with certain medicines to quickly and sufficiently eliminate Leflunomide ratiopharm from your body, thereby reducing the risk to your child.
Do nottake Leflunomide ratiopharm while breastfeeding, as leflunomide passes into breast milk.
Driving and using machines
Leflunomide ratiopharm may make you feel dizzy, which may affect your ability to concentrate and react. If this happens, do not drive or use machines.
Leflunomide ratiopharm contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Leflunomide ratiopharm contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet; this is essentially "sodium-free".
Leflunomide ratiopharm contains soy lecithin
Do not use this medicine if you are allergic to peanuts or soy.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
The usual initial dose of Leflunomide ratiopharm is 100 mg once daily for the first three days. After this, most people need a dose of:
Takethe tablet with plenty of water.
It may take about 4 weeks or even longer before you start to feel better. Some patients may even notice further improvement after 4 or 6 months of treatment.
Leflunomide ratiopharm is usually taken for long periods of time.
If you take moreLeflunomide ratiopharmthan you should
If you take more Leflunomide ratiopharm than you should, consult your doctor or any other healthcare service. If possible, take the tablets or the box with you to show the doctor.
If you forget to takeLeflunomide ratiopharm
If you forget to take a dose, take it as soon as you remember, unless it is almost time for your next dose. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, Leflunomida ratiopharm can cause adverse effects, although not all people suffer from them.
Inform your doctor immediately and stop taking Leflunomida ratiopharm:
Inform your doctor immediatelyif you experience:
Frequent Adverse Reactions (may affect up to one in 10 patients)
Uncommon Adverse Reactions (may affect up to one in 100 patients)
Rare Adverse Reactions (may affect up to one in 1,000 patients)
Very Rare Adverse Reactions (may affect up to one in 10,000 patients)
Other adverse reactions such as kidney failure, decrease in uric acid levels in the blood, pulmonary hypertension, male infertility (this effect is reversible once treatment with this medication is stopped), cutaneous lupus (characterized by skin rash/erythema in sun-exposed areas), psoriasis (new or worsening), DRESS syndrome, and skin ulcers (round, open sores in the skin through which underlying tissues can be seen), may occur with an unknown frequency.
Reporting Adverse Effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the outer carton and on the bottle after EXP. The expiration date is the last day of the month indicated.
Keep the bottle tightly closed to protect it from moisture.
Medicines should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Leflunomida ratiopharm
Each film-coated tablet contains 20 mg of leflunomide.
Appearance of the Product and Package Contents
Leflunomida ratiopharm 20 mg film-coated tablets EFG are white to off-white, round tablets with a diameter of approximately 8 mm and a break line on one side. The tablet can be divided into two equal halves.
The tablets are packaged in bottles.
They are available in package sizes of 30 or 100 film-coated tablets per bottle.
Not all package sizes may be marketed.
Marketing Authorization Holder
ratiopharm GmbH
Graf-Arco-Straße 3,
89079 Ulm
Germany
Manufacturer
Haupt Pharma Münster GmbH
Schleebrüggenkamp 15
48159 Münster
Germany
Merckle GmbH
Ludwig-Merckle-Straße 3
89143 Blaubeuren
Germany
You can obtain more information about this medication by contacting the local representative of the marketing authorization holder.
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG Tél/Tel: +32 3 820 73 73 | Lietuva UAB Teva Baltics Tel: +370 5 266 0203 |
България Тева Фарма България ЕООД Тел: +359 24899585 | Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland Tél/Tel: +49 73140202 |
Česká republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007111 | Magyarország Teva Gyógyszergyár Zrt. Tel.: +36 12886400 |
Danmark Teva Denmark A/S Tlf: +45 44985511 | Malta Teva Pharmaceuticals Ireland, L-Irlanda Tel: +44 2075407117 |
Deutschland ratiopharm GmbH Tel: +49 73140202 | Nederland Teva Nederland B.V. Tel: +31 8000228400 |
Eesti UAB Teva Baltics Eesti filiaal Tel: +372 6610801 | Norge Teva Norway AS Tlf: +47 66775590 |
Ελλάδα Specifar A.B.E.E. Τηλ: +30 2118805000 | Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070 |
España Teva Pharma, S.L.U. Tél: + 34 913873280 | Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459300 |
France Teva Santé Tél: +33 155917800 | Portugal ratiopharm - Comércio e Industria de Produtos Farmacêuticos, Lda. Tel: +351 214767550 |
Hrvatska Pliva Hrvatska d.o.o. Tel: +385 13720000 | România Teva Pharmaceuticals S.R.L Tel: +40 212306524 |
Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407117 | Slovenija Pliva Ljubljana d.o.o. Tel: +386 15890390 |
Ísland Teva Pharma Iceland ehf. Sími: +354 5503300 | Slovenská republika TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267911 |
Italia Teva Italia S.r.l. Tel: +39 028917981 | Suomi/Finland Teva Finland Oy Puh/Tel: +358 201805900 |
Κύπρος Specifar A.B.E.E. Ελλάδα Τηλ: +30 2118805000 | Sverige Teva Sweden AB Tel: +46 42121100 |
Latvija UAB Teva Baltics filiale Latvija Tel: +371 67323666 | United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Date of Last Revision of this Leaflet:{MM/AAAA}.
Other Sources of Information
Detailed information about this medication is available on the European Medicines Agency website http://www.ema.europa.eu.